Stock vs Stock Comparison

Artivion, Inc. vs Johnson & Johnson

JNJ wins the Tale of the Tape 6–3.

AORT
JNJ$223.24

🏆 Tale of the Tape

36
AORTJNJ
2.2%Profitability (Net Margin)28.5%
166.9xValuation (P/E)26.1x
4.2%Efficiency (ROIC)18.3%
7/9Health (Piotroski F)4/9
3.2Safety (Altman Z)4.0
13.6%Growth (Rev YoY)6.0%
Risk (Sharpe 1Y)2.69
0.97xBalance Sheet (D/E)1.44x
0.05%FCF Yield3.25%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Fundamentals

MetricAORTJNJ
Market Cap$1.7B$542.4B
P/E Ratio166.9x26.1x
Forward P/E30.3x17.7x
P/B3.74x6.68x
Dividend Yield2.38%
Beta1.640.26

Quantitative Metrics

MetricAORTJNJ
DCF Fair Value$134.24
DCF Upside-43.6%
Piotroski F7/94/9
Altman Z3.233.97
Beneish M-2.41-2.27
FCF Yield0.05%3.25%
Net Debt/EBITDA2.4x0.5x
ROIC4.2%18.3%
WACC13.6%7.7%
ROIC – WACC-9.4pp10.5pp
Gross Margin64.4%67.9%
Net Margin2.2%28.5%
Rev Growth YoY13.6%6.0%
Sharpe (1Y)2.69
Max Drawdown 3Y-16.0%
FCF Payout Ratio64%

AORT Price

Loading chart...

JNJ Price

Loading chart...

ETF Exposure

AORT found in:

XHE1.07%
SLYG0.12%
VFMO0.07%
SPSM0.06%
VHT0.02%
SPTM0.00%

JNJ found in:

XLV10.42%
IYH10.14%
VHT8.84%
HDV6.84%
MTUM3.76%
DIA2.83%
MGV2.75%
DGRO2.64%
VIG2.49%
VYM2.30%
VTV2.16%
DGRW2.02%
SCHV2.02%
IWD1.94%
QUS1.81%
XPH1.74%
VONV1.69%
NOBL1.58%
VFMV1.42%
VFMO1.02%
SCHX0.96%
SPYG0.94%
SDY0.93%
VOO0.90%
SCHB0.90%
SPY0.87%
IVV0.85%
VONE0.84%
SPTM0.81%
VTI0.80%
SPYV0.79%
SPLG0.76%
ITOT0.75%
URTH0.70%
ACWI0.57%
VT0.49%
RSP0.21%
VFVA0.15%
ONEO0.05%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

AORT vs JNJ: Head-to-Head Analysis

Artivion, Inc. (AORT) and Johnson & Johnson (JNJ) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, JNJ leads 6–3 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, AORT generates a return on invested capital (ROIC) of 4.2% compared to JNJ's 18.3%. This suggests JNJ is more effective at deploying capital to generate shareholder returns.

AORT appears in 6 ETFs tracked by SecuritiesDB, while JNJ appears in 39 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, AORT or JNJ?

Our quantitative analysis compares AORT and JNJ across nine fundamental dimensions. JNJ wins the Tale of the Tape 6–3. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are AORT and JNJ correlated?

Correlation data is not yet available for this pair. Check back after both stocks have sufficient trading history.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.